Evidence map›Paper›PMID 32082975›Full record

ArticleActa pharmaceutica Sinica. B2020

3-

Wan Li, Liwen Ren, Xiangjin Zheng, Jinyi Liu, Jinhua Wang, Tengfei Ji, Guanhua Du

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. MS275 Inhibits Neuroblastoma Cell Growth by Mediating H3K27ac/PROX1 Axis In Silico and In Vitro.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. The potential role of miR-155 in the tumorigenesis of cervical cancer.Frontiers in cell and developmental biology · 2025
    Review
  10. Article
  11. Quantitative mass spectrometry imaging: therapeutics & biomolecules.Chemical communications (Cambridge, England) · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wan LiThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Liwen RenThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Xiangjin ZhengThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Jinyi LiuThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Jinhua WangThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Tengfei JiKey Laboratory of Drug Target Research and Drug Screen, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Guanhua DuThe State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100050, China.
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is the most common and aggressive primary tumor in the central nervous system, accounting for 12%-15% of all brain tumors. 3-

Indexed as

AKBAAKBA, 3-O-acetyl-11-keto-β-boswellic acidAutophagyDAPI, 4′,-6-diamidino-2-phenylindoleG3P, glycerol-3-phosphateG6P, glucose-6-phosphateGBM, glioblastomasGL/FFA, glycerolipid/free fatty acidGlioblastomaIDH1/2, isocitrate dehydrogenases 1/2ITO, indium tin oxideLA, linoleic acidMALDI-MSIMALDI-MSI, matrix-assisted laser desorption ionization-mass spectrometry imagingNAA, N-acetyl-l-aspartic acidNEDC, N-(1-naphthyl) ethylenediamine dihydrochlorideOA, oleic acidPA, phosphatidic acidPE, phosphatidylethanolaminePG, phosphatidylglycerolsPhospholipidsPI, phosphatidylinositolPS, phosphatidylserineTIC, total ion currentTMZ, temozolomide

Identifiers

PMID32082975
PMCPMC7016292
OpenAlexW2999520578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.